Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, shares hot topics in renal cell carcinoma from the ASCO GU Cancers Symposium 2023, including updated data in cabozantinib and nivolumab showing a consistent overall-survival (OS) benefit, as well updated biomarker data for cabozantinib and nivolumab with PD-1 and PD-L1. Prof. Powles additionally highlights clinical trials to look out for in the future, including the Phase III CONTACT-03 (NCT04338269) trial investigating cabozantinib with atezlimzumab and a Phase III (NCT04195750) trial assessing belzutifan versus everolimus. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.